ORLANDO, FL--(Marketwired - Mar 20, 2014) - LENSAR, Inc., today announced it closed a deal with Optegra to install the LENSAR™ Laser System for refractive cataract surgery across all of its hospitals in the United Kingdom (U.K.). 

"Our experience in evaluating this technology over the past year confirms that we can make surgery as accurate and predictable as possible by using LENSAR's 3-D custom imaging," said Sundeep Kheterpal, an ophthalmic surgeon and Director of Laser Cataract Surgery for Optegra. "We firmly believe this is the future of cataract and refractive surgery."

Optegra will become the first U.K. national eye care provider to offer LENSAR's intelligent laser and superior imaging technology for anterior capsulotomy, lens fragmentation and corneal and arcuate incisions. It will be rolled out to all Optegra hospitals during the first quarter of 2014. 

"Surgeons around the world are reporting that the LENSAR Laser System is redefining performance and surgical efficiency, enabling them to handle even the most difficult cases, improving safety and patient outcomes. We are glad to see our systems implemented in these hospitals throughout the United Kingdom," said Nick Curtis, LENSAR CEO.

LENSAR's Augmented Reality™ imaging technology rotates around the eye and takes scanning images at multiple angles to locate and identify the relevant ocular surfaces, measuring them and capturing exact biometric data. This information is then used to create a 3-D model of the anterior anatomy to help guide customized treatment and precise laser placement of each laser pulse. LENSAR's Augmented Reality imaging provides the surgeon with unsurpassed clarity and accuracy giving them the information they need to plan and perform an individualized procedure on each patient.

About LENSAR, Inc.
LENSAR, Inc. is a leader in the development and commercialization of an intelligent femtosecond cataract laser and superior imaging, measurement and 3-D modeling technology. The LENSAR Laser System has been cleared by the FDA for anterior capsulotomy, lens fragmentation and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only. For more information, please visit www.lensar.com.

Contact Information:

Media Contact:
Capwell Communications